Neumora Therapeutics, Inc. (NMRA) bonds
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.47+0.01 (+1.37%)
Close on Nov 11, 2026Market cap $88.87MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$112.91M
$60.00M due within a year
Net debt
-$3.92M
After $116.83M of cash
Implied interest rate
3.51%
FY2025 interest ÷ average debt
Interest coverage
-120.0×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Neumora Therapeutics's 10-Q for the period ended Jun 30, 2026
Neumora Therapeutics's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Expires |
|---|---|---|
| Term Loans | $125.00M | May 1, 2029 |
See a number that looks wrong?